These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2946224)

  • 21. Effects of D-002, a product isolated from beeswax, on gastric symptoms of patients with osteoarthritis treated with piroxicam: a pilot study.
    Illnait J; Terry H; Más R; Fernández L; Carbajal D
    J Med Food; 2005; 8(1):63-8. PubMed ID: 15857212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimum effective dose of etodolac for the treatment of rheumatoid arthritis.
    Jacob G; Messina M; Kennedy J; Epstein C; Sanda M; Mullane J
    J Clin Pharmacol; 1986 Mar; 26(3):195-202. PubMed ID: 2937811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee.
    Watson MC; Brookes ST; Kirwan JR; Faulkner A
    Cochrane Database Syst Rev; 2000; (2):CD000142. PubMed ID: 10796306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A new non-steroidal anti-inflammatory drug pirprofen (rengasil) in the treatment of rheumatoid arthritis and osteoarthrosis].
    Sigidin IaA; Pokryshkin VI
    Ter Arkh; 1987; 59(4):73-6. PubMed ID: 2954253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis.
    Freitas GG
    Curr Med Res Opin; 1990; 12(4):255-62. PubMed ID: 2150187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
    Hunt RH; Bowen B; Mortensen ER; Simon TJ; James C; Cagliola A; Quan H; Bolognese JA
    Am J Med; 2000 Aug; 109(3):201-6. PubMed ID: 10974182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose etodolac in rheumatoid arthritis: a review of early studies.
    Spencer-Green G
    J Rheumatol Suppl; 1997 Feb; 47():3-9; discussion 48-50. PubMed ID: 9035014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of etodolac SR and naproxen on gastro-intestinal blood loss.
    Leese P
    Curr Med Res Opin; 1992; 13(1):13-20. PubMed ID: 1468240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee.
    Perpignano G; Bogliolo A; Puccetti L
    Int J Clin Pharmacol Res; 1994; 14(5-6):203-16. PubMed ID: 7672877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy.
    Briancon D
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():63-72. PubMed ID: 2525985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lornoxicam in clinical practice.
    Berry H; Ollier S
    Postgrad Med J; 1990; 66 Suppl 4():S41-5. PubMed ID: 2284220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
    Eversmeyer W; Poland M; DeLapp RE; Jensen CP
    Am J Med; 1993 Aug; 95(2A):10S-18S. PubMed ID: 8356997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
    Colebatch AN; Marks JL; Edwards CJ
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration.
    Patoia L; Clausi G; Farroni F; Alberti P; Fugiani P; Bufalino L
    Eur J Clin Pharmacol; 1989; 36(6):599-604. PubMed ID: 2673795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
    Lister BJ; Poland M; DeLapp RE
    Am J Med; 1993 Aug; 95(2A):2S-9S. PubMed ID: 8356999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats.
    Tachibana M; Inoue N; Yoshida E; Matsui M; Ukai Y; Yano J
    Pharmacology; 2003 Jun; 68(2):96-104. PubMed ID: 12711837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.
    Balfour JA; Buckley MM
    Drugs; 1991 Aug; 42(2):274-99. PubMed ID: 1717225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of faecal blood loss caused by tenoxicam and piroxicam in normal healthy male volunteers.
    Bird HA; Hill J; Haw WM; Dixon JS; Harris PA; Wright V
    Curr Med Res Opin; 1985; 9(8):524-8. PubMed ID: 3875450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large-scale open trials with etodolac (Lodine) in France: an assessment of safety.
    Benhamou CL
    Rheumatol Int; 1990; 10 Suppl():29-34. PubMed ID: 2150569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology, clinical efficacy, and adverse effects of piroxicam, a new nonsteroidal anti-inflammatory agent.
    Dahl SL; Ward JR
    Pharmacotherapy; 1982; 2(2):80-90. PubMed ID: 6765393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.